Wave Life Sciences Ltd. (NASDAQ:WVE) finished Friday with a subtraction of $0.0 to close at $7.00, a downside of 0.00 percent. An average of 586,120 shares of common stock have been traded in the last five days. There was a gain of $0.59 in the past week, and it reached a new high 16 times over the past 12 months. The last 20 days have seen an average of 1,378,025 shares traded, while the 50-day average volume stands at 748,574.
WVE stock has increased by 65.09% in the last month. The company shares reached their 1-month lowest point of $3.53 on 12/12/22. With the stock rallying to its 52-week high on 12/30/22, shares of the company touched a low of $1.16 and a high of $7.05 in 52 weeks. It has reached a new high 16 times so far this year and achieved 122.93% or $3.86 in price. In spite of this, the price is down -0.71% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
WVE stock investors should be aware that Wave Life Sciences Ltd. (WVE) stock had its last reported insider trading activity 240 days ago on Jun 16. In this transaction, the insider spent $28,748., Francis Chris, disposed of 10,867 shares at a price of $1.72 on May 05. The insider now owns more than $18,691 worth of shares. Prior to that, Chief Financial Officer Moran Kyle went on to Sale 5,021 shares at $1.72 each on May 05. An amount of $8,636 was transacted.
Wave Life Sciences Ltd. (WVE) stock’s beta is -0.79. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 142.63.
The quick ratio of Wave Life Sciences Ltd. for the three months ended June 29 was 2.00, and the current ratio was 2.00, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $167.98 million compared to revenue of $40.96 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Wave Life Sciences Ltd.’s return on assets was -79.50%.
For the three-month period that ended June 29, Wave Life Sciences Ltd. had $25.04 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$39.0 million in the quarter, while revenues of -$41.3 million were grew 84.03%. The analyst consensus anticipated Wave Life Sciences Ltd.’s latest quarter earnings to come in at -$0.54 per share, but it turned out to be -$0.62, a -14.80% surprise. For the quarter, EBITDA amounted to -$36.3 million. Shareholders own equity worth $86.9 million.
From a technical analysis perspective, let’s take a brief look at Wave Life Sciences Ltd. (WVE) price momentum. RSI 9-day as of the close on 30 December was 73.79%, suggesting the stock is Overbought, with historical volatility in this time frame at 83.67%.
As of today, WVE’s price is $6.63 +9.20% or $0.59 from its 5-day moving average. WVE is currently trading +60.92% higher than its 20-day SMA and +185.71% higher than its 100-day SMA. However, the stock’s current price level is +34.87% above the SMA50 and +205.68% above the SMA200.
The stochastic %K and %D were 96.30% and 91.78%, respectively, and the average true range (ATR) was 0.62. With the 14-day stochastic at 97.47% and the average true range at 0.61, the RSI (14) stands at 70.07%. The stock has reached 0.61 on the 9-day MACD Oscillator while the 14-day reading was at 1.05.
The consensus rating for Wave Life Sciences Ltd. (WVE) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell WVE, while 3 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is WVE’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $17.00, with a median target of $7.00. Taking a look at these predictions, the average price target given by analysts for Wave Life Sciences Ltd. (WVE) stock is $8.57.